Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls

Immunity & Ageing

Ove Andersen³  Jesper Eugen-Olsen⁵  Jan Gerstoft⁴  Frank Krieger Jensen²  Jens Henrik Henriksen¹  Janne Petersen⁵  Anne Langkilde⁵ 

[1] Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, Hvidovre, DK-2650, Denmark;Department of Radiology, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, Hvidovre, DK-2650, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, Hvidovre, DK-2650, Denmark;Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, København Ø, DK-2100, Denmark;Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Kettegård Alle 30, Hvidovre, DK-2650, Denmark

关键词: Leptin;    IL-6;    Lipodystrophy;    Obesity;    suPAR;    HIV;    Sarcopenia;    Aging;    Inflammation;   

Others  :  1221901
DOI  :  10.1186/s12979-015-0036-x

 received in 2015-03-09, accepted in 2015-07-24,  发布年份 2015

【 摘 要 】

Background

HIV-infected patients could exhibit accelerated ageing, since age-associated complications like sarcopenia; increased inflammation; lipodystrophy with loss of subcutaneous adipose tissue and/or gain of visceral adipose tissue (VAT); and cardiovascular disease occur at an earlier age. Inflammation is involved in age-associated complications. However, it is not understood whether it is the same inflammatory changes that are involved in the various ageing-associated complications. Our objective was to study whether leptin, interleukin 6 (IL-6), and soluble urokinase plasminogen activator receptor (suPAR) were associated distinctively with adiposity, lipodystrophy and sarcopenia, in HIV-infected patients and healthy Controls.

Results

Systemic leptin levels were significantly higher in patients with lipodystrophy than without, whereas there was no difference in IL-6 or suPAR levels. Leptin was significantly positively associated with fat mass index (FMI) and abdominal VAT, but not with lean mass index (LMI). IL-6 was significantly associated with both FMI and VAT, and low LMI. High suPAR was associated with low LMI, and weakly with high FMI and VAT.

Conclusions

Leptin reflected adiposity- and lipodystrophy-related inflammation, but not sarcopenia. IL-6 reflected both adiposity-, but also sarcopenia-related inflammation; and suPAR was a marker of sarcopenia-related inflammation. Our results indicate that different inflammatory processes can be active simultaneously contributing to the systemic low grade inflammatory state. Identifying major contributors to circulating leptin, IL-6, and suPAR levels could levels could therefore improve our understanding of which inflammatory processes are involved in the various age-related complications.

【 授权许可】

   
2015 Langkilde et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

【 参考文献 】

• [1]Lee JK, Bettencourt R, Brenner D, Le T-A, Barrett-Connor E, Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the rancho Bernardo study. Herder C, redaktør. PLoS One. 2012; 7(4):e34218.
• [2]Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A et al.. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010; 268(3):296-308.
• [3]Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB et al.. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002; 57(5):M326-32.
• [4]Ling PR, Schwartz JH, Bistrian BR. Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol. 1997; 272(3 Pt 1):E333-9.
• [5]Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249):665-8.
• [6]Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al.. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207.
• [7]Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H et al.. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012; 27(8):657-65.
• [8]Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La RA et al.. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010; 201(12):1788-95.
• [9]Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E et al.. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011; 53(11):1120-6.
• [10]Buehring B, Kirchner E, Sun Z, Calabrese L. The frequency of low muscle mass and its overlap with low bone mineral density and lipodystrophy in individuals with HIV—a pilot study using DXA total body composition analysis. J Clin Densitom Off J Int Soc Clin Densitom. 2012; 15(2):224-32.
• [11]Haren MT, Malmstrom TK, Miller DK, Patrick P, Perry HM, Herning MM et al.. Higher C-reactive protein and soluble tumor necrosis factor receptor levels are associated with poor physical function and disability: a cross-sectional analysis of a cohort of late middle-aged African Americans. J Gerontol A Biol Sci Med Sci. 2010; 65(3):274-81.
• [12]Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M et al.. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000–2006. HIV Med. 2008; 9(3):142-50.
• [13]Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, Rueda S et al.. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials. 2011; 12(2):89-103.
• [14]Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003; 361(9359):726-35.
• [15]Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther. 2003; 8(6):617-26.
• [16]Giralt M, Domingo P, Guallar JP, Rodriguez de la Concepcion ML, Alegre M, Domingo JC et al.. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy. AntivirTher. 2006; 11(6):729-40.
• [17]Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Jarvinen H. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2008; 295(1):E85-91.
• [18]Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S et al.. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab. 2003; 285(5):E1072-80.
• [19]Schautz B, Later W, Heller M, Peters A, Müller MJ, Bosy-Westphal A. Impact of age on leptin and adiponectin independent of adiposity. Br J Nutr. 2012; 108(2):363-70.
• [20]Moon H-S, Dalamaga M, Kim S-Y, Polyzos SA, Hamnvik O-P, Magkos F, et al. Leptin’s Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals. Endocr Rev. 2013;34(3):377–12.
• [21]Nagy GS, Tsiodras S, Martin LD, Avihingsanon A, Gavrila A, Hsu WC et al.. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003; 36(6):795-802.
• [22]Mulligan K, Khatami H, Schwarz J-M, Sakkas GK, DePaoli AM, Tai VW et al.. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009; 94(4):1137-44.
• [23]Sekhar RV, Jahoor F, Iyer D, Guthikonda A, Paranilam J, Elhaj F et al.. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome. Metabolism. 2012; 61(10):1395-403.
• [24]Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L et al.. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012; 303(3):E410-21.
• [25]Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012; 8(8):457-65.
• [26]Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015; 14(1):58-74.
• [27]Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008; 80(2):209-16.
• [28]Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers. 2009; 27(3):157-72.
• [29]Langkilde A, Petersen J, Klausen HH, Henriksen JH, Eugen-Olsen J, Andersen O. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography—a cross sectional cohort study. PLoS One. 2012; 7(12):e51698.
• [30]Lyngbæk S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2012;167(3):781–5.
• [31]Kohara K, Ochi M, Tabara Y, Nagai T, Igase M, Miki T. Leptin in sarcopenic visceral obesity: possible link between adipocytes and myocytes. PLoS One. 2011; 6(9):e24633.
• [32]Lee BT, Ahmed FA, Hamm LL, Teran FJ, Chen C-S, Liu Y et al.. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease. BMC Nephrol. 2015; 16:77. BioMed Central Full Text
• [33]Wrann CD, Rosen ED. New insights into adipocyte-specific leptin gene expression. Adipocyte. 2012; 1(3):168-72.
• [34]Isshiki H, Akira S, Tanabe O, Nakajima T, Shimamoto T, Hirano T et al.. Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol Cell Biol. 1990; 10(6):2757-64.
• [35]Kang SH, Brown DA, Kitajima I, Xu X, Heidenreich O, Gryaznov S et al.. Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-6 promotor. J Biol Chem. 1996; 271(13):7330-5.
• [36]Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ et al.. Leptin regulates proinflammatory immune responses. FASEB J Off Publ Fed Am Soc Exp Biol. 1998; 12(1):57-65.
• [37]Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab. 2004; 89(11):5577-82.
• [38]Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia. 2000; 43(12):1498-506.
• [39]Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007; 92(3):1023-33.
• [40]Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E et al.. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005; 46(11):2347-55.
• [41]Couillard C, Mauriège P, Imbeault P, Prud’homme D, Nadeau A, Tremblay A et al.. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obes Relat Metab Disord J Int Assoc Study Obes. 2000; 24(6):782-8.
• [42]Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al.. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82(12):4196-200.
• [43]Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002; 51(12):3391-9.
• [44]Bryer SC, Koh TJ. The urokinase-type plasminogen activator receptor is not required for skeletal muscle inflammation or regeneration. Am J Physiol Regul Integr Comp Physiol. 2007; 293(3):R1152-8.
• [45]DiPasquale DM, Cheng M, Billich W, Huang SA, van Rooijen N, Hornberger TA et al.. Urokinase-type plasminogen activator and macrophages are required for skeletal muscle hypertrophy in mice. Am J Physiol Cell Physiol. 2007; 293(4):C1278-85.
• [46]Sandri M, Barberi L, Bijlsma AY, Blaauw B, Dyar KA, Milan G et al.. Signalling pathways regulating muscle mass in ageing skeletal muscle. The role of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology. 2013; 14(3):303-23.
• [47]Lluís F, Roma J, Suelves M, Parra M, Aniorte G, Gallardo E et al.. Urokinase-dependent plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood. 2001; 97(6):1703-11.
• [48]Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T et al.. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS. 2003; 17(10):1503-11.
• [49]Langkilde A, Andersen O, Henriksen JH, Langberg H, Petersen J, Eugen-Olsen J. Assessment of in situ adipose tissue inflammation by microdialysis. Clin Physiol Funct Imaging. 2014;35(2):110–9.
• [50]Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, Volund A et al.. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism. 2003; 52(10):1343-53.
• [51]Hansen BR, Haugaard SB, Jensen FK, Jensen JEB, Andresen L, Iversen J et al.. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med. 2010; 11(4):266-75.
• [52]Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: advances in models and methods. Annu Rev Nutr. 1997; 17:527-58.
• [53]Kelly TL, Wilson KE, Heymsfield SB. Dual Energy X-Ray Absorptiometry Body Composition Reference Values from NHANES. PLoS One. 2009; 4(9):e7038.
• [54]Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al.. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16):1640-5.
• [55]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9.